Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, enrolling over 100 participants and planning an interim analysis in January 2026. Additionally, the company has secured a $13.8 million R&D tax incentive funding facility and completed a scale-up batch of Xanamem tablets, positioning itself for potential commercialization and partnerships.
More about Actinogen Medical
Actinogen Medical is a biotechnology company focused on developing innovative treatments for neurological conditions, particularly Alzheimer’s disease. The company is engaged in clinical trials and research to advance its primary product, Xanamem, which targets elevated blood biomarkers associated with Alzheimer’s.
Average Trading Volume: 7,733,709
Technical Sentiment Signal: Sell
Current Market Cap: A$79.43M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.